Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

BACKGROUND: The treatment of patients with malignant brain tumors remains a major oncological problem. The median survival of patients with glioblastoma multiforme (GBM), the most malignant type, is only 15 months after initial diagnosis and even less after tumor recurrence. Improvements of standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Geletneky, Karsten, Huesing, Johannes, Rommelaere, Jean, Schlehofer, Joerg R, Leuchs, Barbara, Dahm, Michael, Krebs, Ottheinz, von Knebel Doeberitz, Magnus, Huber, Bernard, Hajda, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425127/
https://www.ncbi.nlm.nih.gov/pubmed/22436661
http://dx.doi.org/10.1186/1471-2407-12-99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425127/
https://www.ncbi.nlm.nih.gov/pubmed/22436661
http://dx.doi.org/10.1186/1471-2407-12-99

Ejemplares similares